[White Paper] Acylated and unacylated ghrelin measurement: Application to metabolic diseases

Obesity is considered to be one of the main health challenges of the 21st century. According to the World Health Organization, at least 2.8 million people die each year as a result of being overweight or obese, a number that is significantly increasing each decade.
Obesity is considered to be a metabolic disease, caused by an energy imbalance between the calories consumed and spent. Metabolic processes are defined as the reactions that sustain life in organisms, with three distinct purposes: converting food to energy, converting food to building blocks for nucleic acids, proteins, and lipids, and processing metabolic wastes. Several hormones have been shown to play a major role in the regulation of metabolic processes. In particular, ghrelin has been identified in 1999 as a gut peptide hormone with a major influence on appetite, food intake, and glucose homeostasis. To investigate the underlying causes of obesity, it is important to be able to measure the levels of the hormones regulating appetite, such as ghrelin or leptin, in biological samples. Bertin Bioreagent, formerly Bertin Pharma, is the first company to have developed ELISA kits to precisely assess the levels of the two forms of ghrelin, acylated and unacylated with high sensitivity in biological samples from various species.
Today, Bertin Bioreagent offers a complete set of assays that allow researchers to measure acylated and unacylated ghrelin and that are compatible with all collection procedures.